| Name | Title | Contact Details |
|---|
For more than 25 years, SelectHealth has been committed to helping members stay healthy, offering superior service, and providing access to the highest quality of care.
Austill's specializes in providing pediatric therapy services to School Districts, Early Intervention Programs, and County-Wide Regional Special Education providers. Since 1984, Austill's has provided therapy for educational programs. We customize all
Hillcrest Educational Foundation is a private not-for-profit agency that provides a range of individualized and comprehensive clinical, psychological and special education services for children, adolescents and families in Berkshire County, MA and the Northeast. The students served by Hillcrest in nonresidential and residential programs have complex psychiatric, behavioral and/or developmental disorders, including Autism Spectrum Disorders, and a variety of high-risk behaviors. The programs and services provided by the Hillcrest Educational Foundation are state licensed and certified, and Hillcrest Educational Centers, including Hillcrest Community Support Services, is accredited in behavioral health care by the Joint Commission.
Aventine HealthSciences is a Montclair, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.